Verona Pharma plc — Director's Dealing 2023

Nov 8, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2023-11-06

Reporting Person: EBSWORTH DAVID R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-06	Ordinary Shares	P	160000	$1.9755	Acquired	844643	Direct

Footnotes

F1: Unless otherwise indicated, reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were purchased in multiple transactions at per share prices ranging from $1.9131 to $2.00, equivalent to $15.3050 to $16.00 per ADS. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F3: Consists of (i) 844,640 Ordinary Shares represented by 105,580 ADSs; and (ii) 3 Ordinary Shares.